



UNIVERSITY OF THESSALY

SCHOOL OF MEDICINE

**MASTER IN “BIOMEDICAL RESEARCH METHODOLOGY,
BIostatISTICS AND CLINICAL BIOINFORMATICS”**

Master Thesis

Assessing the quality of Randomized Controlled Trials
examining the efficacy of Human Papilloma Virus (HPV)
vaccines in cervical cancer prevention.

Αξιολόγηση της ποιότητας των τυχαιοποιημένων ελεγχόμενων
δοκιμών που εξετάζουν την αποτελεσματικότητα των εμβολίων
του ιού των ανθρωπίνων θηλωμάτων (HPV) για την πρόληψη
του καρκίνου του τραχήλου της μήτρας.

Christina Thomopoulou

MSc Mathematician

Supervisor: George Bakalos

Larissa, September 2016

Abstract

Introduction: The human papillomavirus (HPV) causes premalignant and malignant lesions of the cervix. The development of vaccines has helped to prevent diseases related to HPV. Randomized controlled trials (RCTs) are the gold standard by which health care professionals and others make decisions about treatment effectiveness.

Objective: Our objective was to assess the reporting quality of RCTs published the last 10 years, examining the efficacy of HPV vaccines in cervical cancer prevention using a standardized tool based on the Consolidated Standards of Reporting Trials (CONSORT) statement.

Methods: Quality was assessed according to the methodological items in the CONSORT statement. We searched one database, namely, Pubmed. Detailed quality coding was conducted on RCTs, published in English language, between 2006 and 2015. Reporting was evaluated overall, and for pre- and post-CONSORT periods.

Results: 19 of the 37 items (primary and secondary) were reported in less than 50% of the studies. After comparison of the two periods, a non-significant difference ($p>0.05$) was detected in all items.

Conclusion: The quality of the reports on RCTs of efficacy of hpv vaccines in cervical cancer prevention between 2006 and 2015 is moderate. Comparing two time periods, i.e. 2006-2009 and 2010-2015 we noticed there was a non-statistical significant improvement after CONSORT 2010 statement. Thus, researchers should be urged to conform to the CONSORT statement when reporting on RCTs.

Introduction

HPV is a group of more than 150 related viruses, more than 40 of which are typically transmitted through sexual contact and infect the anogenital region of males and females. In particular, HPV16 and HPV18 are known to cause around 70% of cervical cancer cases and the greatest risk of cervical cancer. HPV is a very common virus. Every year, over 27,000 women and men are affected by a cancer caused by HPV. Persistent HPV infection can cause cervical and other cancers. HPV vaccines are vaccines that are used to prevent HPV infection and therefore cervical cancer.

Randomized controlled trials (RCTs) are the gold standard by which health care professionals and others make decisions about treatment effectiveness. RCTs provide information for one clinical intervention compared with another. In randomized controlled trials (RCTs), the participants are allocated to two groups of interventions and control for the comparison of some outcomes between them. So, with the randomized controlled trials (RCTs) we can test the efficacy and effectiveness of HPV vaccines in cervical cancer prevention, which is a good design plan to assess the efficacy of vaccines.

The assessment of new drugs and treatments is important to the clinician in the selection of best therapy. Recent methodological analyses indicate the inadequate reporting and design are associated with biased estimates of treatment effects. So, decisions about some treatments are difficult. It is significant to differentiate between assessing the quality of a trial and the quality of its reporting. The quality of a trial focuses on design quality. The quality of a report can be defined as the provision of information about the design, conduct, and analysis of the trial.

In the mid-1990s, an international group of clinical trialists, statisticians, epidemiologists, and biomedical journal editors developed the Consolidated Standards of Reporting Trials (CONSORT) statement. The CONSORT statement includes a checklist and a flow diagram for reporting RCTs. The checklist is designed to help authors in the reporting of randomised controlled trials (RCTs). Since then, the checklist has experienced some changes. Further meetings of the Group in 1999 and 2000 led to the publication of the revised CONSORT statement 2001.

Following a meeting in January 2007, a further revision was developed and the CONSORT 2010 statement was published on March 24, 2010. The last CONSORT statement published in 2010, included 25 items.

We aimed to assess the quality of randomized controlled trials (RCTs) examining the efficacy of human papillomavirus vaccines in cervical cancer prevention according to the methodological items in the CONSORT statement 2010.

Methods

Studies Selection and Data Extraction

We have selected one database, namely, Pubmed to search all papers published between January 1, 2006 and 2015, with searching language limited to English. Selection of randomized controlled trials (RCTs) was made based on the appearance of the term “efficacy of hpv vaccines in cervical cancer prevention”. A total of 59 articles matched this search criteria. Of these, 5 were not published between 2006 and 2015, 1 was not published in English language, in 21 articles were not found free full texts and 9 were not relevant to topic. So, a final group of 23 RCTs was found. We have chosen all the RCTs concerning the efficacy of hpv vaccines in cervical cancer prevention. Among the selected, the intervention groups were treated with hpv vaccines. Figure I shows a flow chart for the selection of studies considered for inclusion.

A set of quality criteria for evaluating RCTs examining the efficacy of human papillomavirus (HPV) in cervical cancer prevention was compiled using criteria from the CONSORT Statement. The CONSORT statement of 2010 consists of 25 items (refined to 37 items, 25 primary and 12 secondary). According to the CONSORT 2010 checklist we created an evaluation form for each of the 25 items. The result of each item was assessed by yes (1 point) or no (0 point) depending whether the author had reported it.

Statistical Methods

Reporting was evaluated overall and in two publication periods, i.e. 2006-2009 (pre-CONSORT), and 2010-2015 (post-CONSORT).

Additional, reporting was evaluated checking if there is any difference between the journals which endorse CONSORT, compared to those they don't. Data were analyzed using Microsoft Excel 2007 and SPSS software (version 22.0, IBM SPSS). We counted the number of reports which met the standards of CONSORT 2010, and calculated the percentage of application of each standard. Also, we used parametric statistics and we compared pre- and post-CONSORT periods calculating the odds ratio (OR) and the respective 95% confidence interval using Fisher's exact test. A P-value <0.05 was considered statistically significant.

Table 1. Proportion of reporting of 25 data items in a total of 23 RCTs by publication period (pre- and post-CONSORT and combined)*

Data items	Combined [†]	Pre-CONSORT	Post-CONSORT	Odds Ratio and 95% CI [‡]	p-value ^{**}
<i>Title and Abstract</i>					
1a	0.30(7)	0.14(1)	0.37(6)	3.6(0.35, 37.6)	0.37
1b	0.43(10)	0.14(1)	0.56(9)	7.7(0.75, 79.8)	0.09
<i>Introduction</i>					
<i>Background and objectives</i>					
2a	1.0(23)	1.0(7)	1.0(16)	-	-
2b	1.0(23)	1.0(7)	1.0(16)	-	-
<i>Methods</i>					
<i>Trial design</i>					
3a	0.48(11)	0.29(2)	0.56(9)	3.2(0.47, 21.8)	0.37
3b	0.04(1)	0.0(0)	0.06(1)	-	1.000
<i>Participants</i>					
4a	1.0(23)	1.0(7)	1.0(16)	-	-
4b	0.87(20)	0.86(6)	0.88(14)	1.17(0.088, 15.46)	1.000
<i>Interventions</i>					
5	0.83(19)	0.71(5)	0.88(14)	2.8(0.3, 25.5)	0.56
<i>Outcomes</i>					
6a	0.65(15)	0.43(3)	0.75(12)	4(0.6, 26.1)	0.18

6b	0.04(1)	0.0(0)	0.06(1)	-	1.000
<i>Sample size</i>					
7a	0.17(4)	0.0(0)	0.25(4)	-	0.27
7b	0.13(3)	0.14	0.13(2)	0.86(0.65, 11.36)	1.000
<i>Randomisation</i>					
<i>Sequence generation</i>					
8a	0.26(6)	0.29(2)	0.38(6)	0.83(0.1, 6.1)	1.000
8b	0.09(2)	0.14(1)	0.25(4)	0.4(0.21, 7.5)	0.53
<i>Allocation concealment mechanism</i>					
9	0.26(6)	0.29(2)	0.25(4)	0.83(0.1, 6.1)	1.000
<i>Implementation</i>					
10	0.0(0)	0.0(0)	0.0(0)	-	-
<i>Blinding</i>					
11a	0.30(7)	0.14(1)	0.38(6)	3.6(0.35, 37.6)	0.37
11b	0.26(6)	0.14(1)	0.31(5)	2.73(0.26, 29.1)	0.6
<i>Statistical methods</i>					
12a	1.0(23)	1.0(7)	1.0(16)	-	-
12b	0.57(13)	0.29(2)	0.69(11)	5.5(0.78, 38.7)	0.17
<i>Results</i>					
<i>Participant flow</i>					
13a	0.65(15)	0.57(4)	0.69(11)	1.65(0.26, 10.3)	0.66
13b	0.61(14)	0.57(4)	0.63(10)	1.25(0.21, 7.6)	1.000
<i>Recruitment</i>					
14a	0.09(2)	0.0(0)	0.13(2)	-	1.000
14b	0.0(0)	0.0(0)	0.0(0)	-	-
<i>Baseline data</i>					
15	0.78(18)	0.71(5)	0.81(13)	1.7(0.22, 13.67)	0.62
<i>Numbers analyses</i>					
16	0.35(8)	0.14(1)	0.44(7)	4.67(0.45, 48.3)	0.35
<i>Outcomes and estimation</i>					
17a	1.0(23)	1.0(7)	1.0(16)	-	-
17b	0.04(1)	0.0(0)	0.06(1)	-	1.000

Ancillary analyses

18	0.78(18)	0.71(5)	0.81(13)	1.7(0.22, 13.67)	0.62
----	----------	---------	----------	------------------	------

Harms

19	0.39(9)	0.43(3)	0.38(6)	0.8(0.13, 4.87)	1.000
----	---------	---------	---------	-----------------	-------

*Discussion**Limitations*

20	0.7(16)	0.71(5)	0.69(11)	0.9(0.16, 6.2)	1.000
----	---------	---------	----------	----------------	-------

Generalisability

21	0.78(18)	0.71(5)	0.81(13)	1.73(0.22, 13.67)	0.62
----	----------	---------	----------	-------------------	------

Interpretation

22	0.65(15)	0.57(4)	0.69(11)	1.65(0.20, 10.3)	0.66
----	----------	---------	----------	------------------	------

*Other information**Registration*

23	0.52(12)	0.43(3)	0.56(9)	1.7(0.28, 10.3)	0.67
----	----------	---------	---------	-----------------	------

Protocol

24	0.30(7)	0.29(2)	0.31(5)	1.14(0.16, 7.99)	1.000
----	---------	---------	---------	------------------	-------

Funding

25	0.7(16)	0.86(6)	0.63(10)	0.28(0.03, 2.9)	0.37
----	---------	---------	----------	-----------------	------

*CONSORT=Consolidated Standards of Reporting Trials

†The percentage of articles reporting the CONSORT item

¥ Odds ratio of reporting an item at post-CONSORT period relative to pre-CONSORT.


** p-values from Fisher's exact test for testing the association between reporting an item and publication period.

Combined: 2006-2015 (n=23)

Pre-CONSORT: 2006-2009 (n=7)

Post-CONSORT: 2010-2015 (n=16)

Figure I. Flow diagram showing selection of reports for inclusion in study



Results

Our database searching on PubMed identified 547 articles on the efficacy of human papillomavirus vaccines in cervical cancer prevention. Of these 524 were excluded for various reasons. Reasons for study exclusion are given in Figure I. In total, 23 RCTs were selected for analysis and quality assessment. Of these articles, 7 were published in the pre-CONSORT period (2006-2009) and 16 in the post-CONSORT period (2010-2015). The articles were retrieved from 13 journals of which 10 have not endorsed the CONSORT statement (Table 2).

The primary outcome of the study was the number and percentage of items on the CONSORT checklist that were reported between 2006 and 2015. The total number and percentage of RCTs reporting each quality criterion is provided in Table 1 and based on 25 standards of CONSORT 2010.

When the 23 RCTs are considered together, according to the 37 items in CONSORT 2010 checklist, only 4.3% (1/23) reported important changes to methods after trial commencement, changes to trial outcomes after the trial commenced and presentation of both absolute and relative effect sizes, 30.4% (7/23) mentioned "randomization" in the title, blinding to interventions and where the full trial protocol can be accessed, 65.2% (15/23) reported completely defined pre-specified primary and secondary outcome measures, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome and trial interpretation, 78.3% (18/23) reported the baseline data with a table, ancillary analyses and Generalisability, 26.1% (6/23) reported the method used to generate the random allocation sequence, the Allocation concealment mechanism and the similarity of interventions, 8.7% (2/23) reported the type of randomisation and dates defining the periods of recruitment and follow-up, 69.6% (16/23) reported trial limitations and the source of funding, 60.9% (14/23) reported losses and exclusions after randomisation, 39.1% (9/23) reported side effects, 47.8% (11/23) reported description of trial design, 43.5% (10/23) reported structured summary, 87% (20/23) reported settings and locations where the data were collected, 82.6% (19/23) reported the interventions for each group, 17.4% (4/23) reported how sample size was determined, 13% (3/23) reported explanation of any interim analyses and stopping

guidelines, 56.5% (13/23) reported methods for additional analyses, 34.8% (8/23) reported the number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups and 52.5% (12/23) reported the registration number and name of trial registry. 5 of the 37 items (2a, 2b, 4a, 12a and 17a) were reported in all included articles, while 2 items (10 and 14b) were not mentioned at all. Table 3 shows the items reported less often (<25%) and more often (>75%).

After comparison of the two periods, a non-significant improvement ($p>0.05$) was detected in all items. All the items are the same likely to be reported pre- and post- CONSORT 2010 (see respective OR at table 1).

After comparison of the journals, we noticed there was a statistical significant difference ($p<0.05$) between the journals which endorse CONSORT, compared to those they don't only on 3 items (3a, 14a, 22) (see table 3).

Table 2: Distribution of papers by journal

Journal	Papers (%*)	Consort endorser†
Lancet Oncology	1(4.3%)	YES
The new England journal of medicine	2(8.7%)	NO
Clinical and Vaccine Immunology	2(8.7%)	NO
The BMJ	2(8.7%)	NO
Journal of the national cancer institute	2(8.7%)	YES
The official journal of the Japanese cancer association	1(4.3%)	NO
PLOS ONE	2(8.7%)	YES

International journal of cancer	2(8.7%)	NO
American journal of epidemiology	1(4.3%)	NO
Human Vaccines & Immunotherapeutics	1(4.3%)	NO
The journal of infectious diseases	3(13%)	NO
British journal of cancer	1(4.3%)	NO
Others	3(13%)	NO

Table 3. Items reported less often (<25%) and more often (>75%) and comparison between the journals which endorse CONSORT and Not.

<i>Items</i>	<i>Reported less often (<25%)</i>	<i>Reported more often (>75%)</i>	<i>p-value</i>
<i>Title and Abstract</i>			
1a			1.000
1b			0.127
<i>Introduction</i>			
2a		✓	-
2b		✓	-
<i>Methods</i>			
3a			0.037<0.05
3b	✓		1.000
4a		✓	-
4b		✓	0.0539
5		✓	0.539
6a			0.122
6b	✓		1.000
7a	✓		0.539
7b	✓		1.000
8a			1.000
8b	✓		1.000
9			1.000
10	✓		-
11a			0.621
11b			0.576
12a		✓	-
12b			0.339
<i>Results</i>			

13a			0.621
13b			1.000
14a	✓		0.040<0.05
14b	✓		-
15		✓	0.291
16			1.000
17a		✓	-
17b	✓		1.000
18		✓	0.291
19			0.611
<i>Discussion</i>			
20			1.000
21		✓	0.545
22			0.033<0.05
<i>Other information</i>			
23			0.640
24			0.621
25			1.000

Conclusion

There are some limitations to this study. This was a study based only on PubMed searching, in a 10-year period and only in English language. However, only 1 of the articles published in other language and 5 in other dates (not the last 10 years). So, the risk of bias is limited.

The quality of the reports on RCTs of efficacy of hpv vaccines in cervical cancer prevention between 2006 and 2015 is moderate. 9 key methodological items of the CONSORT statement seem poor (0-25%), 10 low (26%-50%), 8 fair (51%-75%) and 10 good (76%-100%). Also, we compared two time periods, i.e. 2006-2009 and 2010-2015. We noticed there was any statistical significant difference between pre- and post-CONSORT 2010 in studies examining the efficacy of hpv vaccines in cervical cancer prevention. So, there was a non-statistical significant improvement after CONSORT 2010 statement.

Generally, the checklist improves the scientific quality of RCTs by assisting authors in the planning, preparing and conducting of RCTs. In conclusion, within the limitations of this study, we have shown that greater attention to quality aspects of design and reporting of RCTs in efficacy of hpv vaccines in cervical cancer prevention is needed and the adoption of the CONSORT statement should be a first step. Thus,

researchers should be urged to conform to the CONSORT statement when reporting on RCTs in future.

References

1. Partsinevelou A¹, Zintzaras E.
Quality of reporting of randomized controlled trials in polycystic ovary syndrome. Trials. 2009 Nov 20;10:106.
2. Süt N¹, Senocak M, Uysal O, Köksalan H. *Assessing the quality of randomized controlled trials from two leading cancer journals using the CONSORT statement.* Hematol Oncol Stem Cell Ther. 2008 Jan-Mar;1(1):38-43.
3. Mehrazmay A¹, Karambakhsh A¹, Salesi M².
Reporting Quality Assessment of Randomized Controlled Trials Published in Nephrology Urology Monthly Journal. Nephrourol Mon. 2015 Jul 1;7(4):e28752.
4. Fan FF¹, Xu Q², Sun Q², Zhao SJ¹, Wang P¹, Guo XR³.
Assessment of the reporting quality of randomized controlled trials on treatment of coronary heart disease with traditional Chinese medicine from the chinese journal of integrated traditional and Western medicine: a systematic review. PLoS One. 2014 Jan 28;9(1):e86360.
5. Montenegro R¹, Needleman I, Moles D, Tonetti M. *Quality of RCTs in periodontology--a systematic review.* J Dent Res. 2002 Dec;81(12):866-70.
6. Bo C¹, Xue Z, Yi G, Zelin C, Yang B, Zixu W, Yajun W.
Assessing the quality of reports about randomized controlled trials of acupuncture treatment on Diabetic Peripheral Neuropathy. PLoS One. 2012;7(7):e38461.
7. Montori VM¹, Wang YG, Alonso-Coello P, Bhagra S.
Systematic evaluation of the quality of randomized controlled trials in diabetes. Diabetes Care. 2006 Aug;29(8):1833-8.
8. Uman LS¹, Chambers CT, McGrath PJ, Kisely S, Matthews D, Hayton K. *Assessing the quality of randomized controlled trials examining psychological interventions for pediatric*

- procedural pain: recommendations for quality improvement. J Pediatr Psychol.* 2010 Aug;35(7):693-703.
9. Struyf F, Colau B, Wheeler CM, Naud P, Garland S, Quint W, Chow SN, Salmerón J, Lehtinen M, Del Rosario-Raymundo MR, Paavonen J, Teixeira JC, Germar MJ, Peters K, Skinner SR, Limson G, Castellsagué X, Poppe WA, Ramjattan B, Klein TD, Schwarz TF, Chatterjee A, Tjalma WA, Diaz-Mitoma F, Lewis DJ, Harper DM, Molijn A, van Doorn LJ, David MP, Dubin G; HPV PATRICIA Study Group. *Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA.* Clin Vaccine Immunol. 2015 Feb;22(2):235-44.
 10. Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, Zahaf T, Catteau G, Geeraerts B, Descamps D. *Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.* Hum Vaccin Immunother. 2014;10(8):2147-62.
 11. Giuliano AR, Botha MH, Zeier M, Abrahamsen ME, Glashoff RH, van der Laan LE, Papenfuss M, Engelbrecht S, Schim van der Loeff MF, Sudenga SL, Torres BN, Kipping S, Taylor D. *High HIV, HPV, and STI prevalence among young Western Cape, South African women: EVRI HIV prevention preparedness trial.* J Acquir Immune Defic Syndr. 2015 Feb 1;68(2):227-35.
 12. Lang Kuhs KA, Gonzalez P, Rodriguez AC, van Doorn LJ, Schiffman M, Struijk L, Chen S, Quint W, Lowy DR, Porras C, DelVecchio C, Jimenez S, Safaeian M, Schiller JT, Wacholder S, Herrero R, Hildesheim A, Kreimer AR; Costa Rica Vaccine Trial Group. *Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial.* J Infect Dis. 2014 Dec 15;210(12):1890-9.
 13. Zhu FC, Chen W, Hu YM, Hong Y, Li J, Zhang X, Zhang YJ, Pan QJ, Zhao FH, Yu JX, Zhang YS, Yang X, Zhang CF, Tang

- H, Zhang H, Lebacqz M, David MP, Datta SK, Struyf F, Bi D, Descamps D;HPV-039 study group. *Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial*. Int J Cancer. 2014 Dec 1;135(11):2612-22.
14. Yoshikawa H, Ebihara K, Tanaka Y, Noda K. *Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years*. Cancer Sci. 2013 Apr;104(4):465-72.
 15. Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, Huh WK, Sings HL, James MK, Haupt RM; FUTURE I and II Study Group. *Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data*. BMJ. 2012 Mar 27;344:e1401
 16. Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Catteau G, Dobbelaere K, Schuind A, Descamps D. *Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study*. Hum Vaccin. 2011 Dec;7(12):1374-86.
 17. Kreimer AR, González P, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jiménez S, Schiller JT, Lowy DR, van Doorn LJ, Struijk L, Quint W, Chen S, Wacholder S, Hildesheim A, Herrero R; CVT Vaccine Group. *Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial*. Lancet Oncol. 2011 Sep;12(9):862-70.
 18. Szarewski A, Poppe WA, Skinner SR, Wheeler CM, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, Castellsagué X, Teixeira JC, Hedrick J, Jaisamrarn U, Limson G, Garland S, Romanowski B, Aoki FY, Schwarz TF, Bosch FX, Harper DM, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group. *Efficacy of the human papillomavirus (HPV)-16/18 AS04-*

- adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer. 2012 Jul 1;131(1):106-16.*
19. Kepka D, Coronado GD, Rodriguez HP, Thompson B. *Evaluation of a radionovela to promote HPV vaccine awareness and knowledge among Hispanic parents. J Community Health. 2011 Dec;36(6):957-65.*
 20. Konno R, Tamura S, Dobbelaere K, Yoshikawa H. *Prevalence and type distribution of human papillomavirus in healthy Japanese women aged 20 to 25 years old enrolled in a clinical study. Cancer Sci. 2011 Apr;102(4):877-82.*
 21. FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R. *Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010 Jul 20;341:c3493.*
 22. Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM. *Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010 Mar 3;102(5):325-39.*
 23. Rowhani-Rahbar A, Mao C, Hughes JP, Alvarez FB, Bryan JT, Hawes SE, Weiss NS, Koutsky LA. *Longer term efficacy of a*

prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine. 2009 Sep 18;27(41):5612-9.

24. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Sings HL, James M, Hesley TM, Barr E. *The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naïve women aged 16-26 years*. J Infect Dis. 2009 Apr 1;199(7):926-35
25. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, James M, Vuocolo S, Hesley TM, Barr E. *The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years*. J Infect Dis. 2009 Apr 1;199(7):936-44.
26. Herrero R, Hildesheim A, Rodríguez AC, Wacholder S, Bratti C, Solomon D, González P, Porras C, Jiménez S, Guillen D, Morales J, Alfaro M, Cyr J, Morrissey K, Estrada Y, Cortés B, Morera LA, Freer E, Schussler J, Schiller J, Lowy D, Schiffman M; Costa Rica Vaccine Trial (CVT) Group. *Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica*. Vaccine. 2008 Sep 2;26(37):4795-808.
27. FUTURE II Study Group. *Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women*

- with virological evidence of HPV infection. J Infect Dis.* 2007 Nov 15;196(10):1438-46.
28. Giuliano AR, Lazcano-Ponce E, Villa L, Nolan T, Marchant C, Radley D, Golm G, McCarroll K, Yu J, Esser MT, Vuocolo SC, Barr E. *Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis.* 2007 Oct 15;196(8):1153-62.
 29. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. *Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med.* 2007 May 10;356(19):1928-43.
 30. FUTURE II Study Group. *Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med.* 2007 May 10;356(19):1915-27.
 31. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh Gv, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E. *High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer.* 2006 Dec 4;95(11):1459-66.